Autism Spectrum Disorder Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021 – 2031

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$10995
Buy Report View Sample

Published: October 28, 2022 Report Code: GDHC252PIDR-ST

Select Item

Autism Spectrum Disorder Market Report Overview

The Autism Spectrum Disorder (ASD) market size was $985.5 million in 2021 and is expected to achieve a CAGR of more than 15% during 2021-2031. ASD, also known as autism, is a highly heterogeneous disorder characterized by varying social and communication impairments and pervasive repetitive behaviors, in addition to a wide range of associated non-core symptoms. The ASD market is chronically underserved, with no approved treatments for the core symptoms or most of the associated non-core symptoms.Autism Spectrum Disorder Market Size

The Autism Spectrum Disorder market research report provides an overview of ASD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

To gain more information on the Autism Spectrum Disorder market forecast, download a free report sample

Market Size (2021) $985.5 million
CAGR (2021 – 2031) >15%
Forecast period 2022-2031
Key Class of Drugs Atypical Antipsychotics, SSRIs, other off-label therapies, and Cannabinoids
Leading Players AbbVie, Acadia Pharmaceuticals, Axial Therapeutics, Bristol Myers Squibb, Confluence Pharmaceuticals, Cox Biosciences, Curemark, Finch Therapeutics, Gedeon Richter, and Jazz Pharmaceuticals

Autism Spectrum Disorder Market Drivers

10 new pipeline products with significantly higher costs of therapy when compared to the cost of the generic therapies will launch throughout the 7MM during the forecast period. Moreover, the potential for novel pharmacological therapies specifically indicated for the core symptoms of ASD, that is a major unmet need in the ASD market, could provide new options for patients.

Autism Spectrum Disorder Market Segmentation by Class of Drugs

The key classes of drugs in the autism spectrum disorder market are Atypical Antipsychotics, SSRIs, other off-label therapies, and Cannabinoids, among others. In 2021, Atypical Antipsychotics were the top-selling class of drugs.

Autism Spectrum Disorder Market Analysis, by Class of Drugs, 2021 (%)

Autism Spectrum Disorder Market Analysis, by Class of Drugs

For more ASD classes of drugs insights, download a free report sample

Autism Spectrum Disorder Market - Competitive Landscape

Some of the leading players in the autism spectrum disorder market are AbbVie, Acadia Pharmaceuticals, Axial Therapeutics, Bristol Myers Squibb, Confluence Pharmaceuticals, Cox Biosciences, Curemark, Finch Therapeutics, Gedeon Richter, and Jazz Pharmaceuticals.

Segments Covered in this Report

Autism Spectrum Disorder Market Class of Drugs Outlook (Value, $ Million, 2021-2031)

  • Atypical Antipsychotics
  • SSRIs
  • Other off-label therapies
  • Cannabinoids

Scope

This report provides

  • Overview of ASD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

  • Annualized ASD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (children, adolescents, and adults) forecast from 2021 to 2031.

  • Strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the ASD therapeutics market.

  • Pipeline analysis, comprehensive data assessing emerging trends and mechanisms of action under development for ASD therapy. The most promising candidates in Phase III and IIb development are profiled.

  • Analysis of the current and future market competition in the global ASD therapeutics market and insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

  • Develop business strategies by understanding the trends shaping and driving the global ASD therapeutics market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ASD therapeutics market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

AbbVie
Acadia Pharmaceuticals
Axial Therapeutics
Bristol Myers Squibb
Confluence Pharmaceuticals
Cox Biosciences
Curemark
Finch Therapeutics
Gedeon Richter
Jazz Pharmaceuticals
Johnson & Johnson
Otsuka
Paxmedica
Roche
Scioto Biosciences
Sumitomo Pharmaceuticals
Vanda Pharmaceuticals
Yamo Pharmaceuticals

Table of Contents

  • 1. Autism Spectrum Disorder: Executive Summary

    • 1.1. Strong growth expected in the ASD market during 2021–31

    • 1.2. Targeting core symptoms is a key R&D strategy for ASD

    • 1.3. Opportunities to fulfil key unmet needs will remain, particularly outside of the US

    • 1.4. Novel late-stage pipeline drugs will be a key driver of growth

    • 1.5. What do physicians think?

  • 2. Introduction

    • 2.1. Catalyst

    • 2.2. Related reports

    • 2.3. Upcoming reports

  • 3. Disease Overview

    • 3.1. Etiology and pathophysiology

      • 3.1.1. Etiology

      • 3.1.2. Pathophysiology

  • 4. Epidemiology

    • 4.1. Disease background

    • 4.2. Risk factors and comorbidities

    • 4.3. Global and historical trends

    • 4.4. Forecast methodology

      • 4.4.1. Sources

      • 4.4.2. Forecast assumptions and methods

      • 4.4.3. Forecast assumptions and methods: total prevalent cases of ASD

      • 4.4.4. Forecast assumptions and methods: diagnosed prevalent cases of ASD – 7MM

    • 4.5. Epidemiological Forecast for Autism Spectrum Disorder (2021–31)

      • 4.5.1. Total prevalent cases of ASD

      • 4.5.2. Age-specific total prevalent cases of ASD

      • 4.5.3. Sex-specific total prevalent cases of ASD

      • 4.5.4. Diagnosed prevalent cases of ASD

      • 4.5.5. Age-specific diagnosed prevalent cases of ASD

      • 4.5.6. Sex-specific diagnosed prevalent cases of ASD

    • 4.6. Discussion

      • 4.6.1. Epidemiological forecast insight

      • 4.6.2. COVID-19 impact

      • 4.6.3. Limitations of the analysis

      • 4.6.4. Strengths of the analysis

  • 5. Disease Management

    • 5.1. Diagnosis and treatment overview

    • 5.2. Additional key opinion leader insights on disease management

  • 6. Competitive Assessment

    • 6.1. Overview

  • 7. Unmet Needs and Opportunity Assessment

    • 7.1. Overview

    • 7.2. Effective treatment options for the core symptoms of ASD

    • 7.3. Improved treatment options for treating irritability associated with ASD

    • 7.4. Treatment options for other symptoms associated with ASD

    • 7.5. Increased numbers of physicians able to diagnose and treat ASD

  • 8. R&D Strategies

    • 8.1. Overview

      • 8.1.1. Targeting the core symptoms

      • 8.1.2. Targeting the microbiome

      • 8.1.3. Label expansion of atypical antipsychotics

    • 8.2. Clinical Trials Design

      • 8.2.1. Endpoints

      • 8.2.2. Inclusion/exclusion criteria

  • 9. Pipeline Assessment

    • 9.1. Overview

    • 9.2. Promising drugs in clinical development

  • 10. Pipeline Valuation Analysis

    • 10.1. Overview

    • 10.2. Competitive assessment

  • 11. Current and Future Players

    • 11.1. Overview

    • 11.2. Deal-making trends

  • 12. Market Outlook

    • 12.1. Global markets

      • 12.1.1. Forecast

      • 12.1.2. Drivers and barriers – global issues

    • 12.2. US

      • 12.2.1. Forecast

      • 12.2.2. Key events

      • 12.2.3. Drivers and barriers

    • 12.3. 5EU

      • 12.3.1. Forecast

      • 12.3.2. Key events

      • 12.3.3. Drivers and barriers

    • 12.4. Japan

      • 12.4.1. Forecast

      • 12.4.2. Key events

      • 12.4.3. Drivers and barriers

  • 13. Appendix

    • 13.1. Bibliography

    • 13.2. Abbreviations

    • 13.3. Methodology

      • 13.3.1. Forecasting methodology

    • 13.4. Primary research – key opinion leaders and payers interviewed for this report

      • 13.4.1. Key opinion leaders

      • 13.4.2. Payers

    • 13.5. Primary research – prescriber survey

    • 13.6. About the authors

      • 13.6.1. Analyst

      • 13.6.2. Therapy Area Director

      • 13.6.3. Epidemiologist

      • 13.6.4. Managing Epidemiologist

      • 13.6.5. Vice President of Disease Analysis and Intelligence

      • 13.6.6. Global Head and EVP of Healthcare Operations and Strategy

  • 14. Contact Us

Table

Table 1: ASD: key metrics in the 7MM

Table 2: Risk factors and comorbidities for ASD

Table 3: DSM-5 criteria for ASD

Table 4: Non-Pharmacological Treatments for Autism Spectrum Disorder

Table 5: Treatment Guidelines for Autism Spectrum Disorder

Table 6: ASD market – global drivers and barriers, 2021–2031

Table 7: Key events impacting sales for ASD in the US, 2021–31

Table 8: ASD market – drivers and barriers in the US, 2021–2031

Table 9: Key events impacting sales for ASD in the 5EU, 2021–31

Table 10: ASD market – drivers and barriers in the 5EU, 2021–2031

Table 11: Key events impacting sales for ASD in Japan, 2021–31

Table 12: ASD market – drivers and barriers in Japan, 2021–2031

Table 13: High-prescribing physicians (non-KOLs) surveyed, by country

Figures

Figure 1: Global sales forecast by country for ASD in 2021 and 2031

Figure 2: Analysis of the company portfolio gap in ASD during the forecast period

Figure 3: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of ASD during the forecast period

Figure 4: 7MM, diagnosed prevalence of ASD, both sexes, %, all ages, 2021

Figure 5: 7MM, sources used and not used to forecast the total prevalent cases of ASD

Figure 6: 7MM, sources used and not used to forecast the diagnosed prevalent cases of ASD

Figure 7: 7MM, total prevalent cases of ASD, N, men and women, all ages, 2021

Figure 8: 7MM age-specific total prevalent cases of ASD, N, men and women, 2021

Figure 9: 7MM total prevalent cases of ASD by sex, N, all ages, 2021

Figure 10: 7MM diagnosed prevalent cases of ASD, N, men and women, all ages, 2021

Figure 11: 7MM age-specific diagnosed prevalent cases of ASD, N, men and women, all ages, 2021

Figure 12: 7MM diagnosed prevalent cases of ASD by sex, N, all ages, 2021

Figure 13: Unmet needs and opportunities in ASD

Figure 14: Overview of the development pipeline in ASD

Figure 15: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for ASD in the 7MM during the forecast period

Figure 16: Competitive assessment of the marketed and pipeline drugs benchmarked against the SOC, Abilify (aripiprazole)

Figure 17: Analysis of the company portfolio gap in ASD during the forecast period

Figure 18: Global (7MM) sales forecast by country for ASD in 2021 and 2031

Figure 19: Global (7MM) sales forecast by class for ASD in 2021 and 2031

Figure 20: Sales forecast by class for ASD in the US in 2021 and 2031

Figure 21: Sales forecast by class for ASD in the 5EU in 2021 and 2031

Figure 22: Sales forecast by class for ASD in Japan in 2021 and 2031

Frequently asked questions

Autism Spectrum Disorder Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021 – 2031 standard reports
Currency USD
$10,995

Can be used by individual purchaser only

Most Popular
$21,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Autism Spectrum Disorder Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021 – 2031 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Central Nervous System reports
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Generic Drugs - Physician Perspective - Thematic Intelligence
$1,495 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Autism Spectrum Disorder Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021 – 2031 in real time.

  • Access a live Autism Spectrum Disorder Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021 – 2031 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more